Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment.
Rizzari C, Putti MC, Colombini A, Casagranda S, Ferrari GM, Papayannidis C, Iacobucci I, Abbenante MC, Sartor C, Martinelli G. Rizzari C, et al. Among authors: putti mc. Hematol Rep. 2014 Sep 30;6(3):5554. doi: 10.4081/hr.2014.5554. eCollection 2014 Aug 26. Hematol Rep. 2014. PMID: 25317319 Free PMC article. Review.
Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia.
Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F, Luciani M, Lo Nigro L, Menna G, Micalizzi C, Santoro N, Testi AM, Zecca M, Biondi A, Pigazzi M, Rutella S, Rondelli R, Basso G, Locatelli F; AIEOP AML Study Group. Pession A, et al. Among authors: putti mc. Blood. 2013 Jul 11;122(2):170-8. doi: 10.1182/blood-2013-03-491621. Epub 2013 May 14. Blood. 2013. PMID: 23673857 Free article. Clinical Trial.
Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study.
Conter V, Valsecchi MG, Parasole R, Putti MC, Locatelli F, Barisone E, Lo Nigro L, Santoro N, Aricò M, Ziino O, Pession A, Testi AM, Micalizzi C, Casale F, Zecca M, Casazza G, Tamaro P, La Barba G, Notarangelo LD, Silvestri D, Colombini A, Rizzari C, Biondi A, Masera G, Basso G. Conter V, et al. Among authors: putti mc. Blood. 2014 Mar 6;123(10):1470-8. doi: 10.1182/blood-2013-10-532598. Epub 2014 Jan 10. Blood. 2014. PMID: 24415536 Free article. Clinical Trial.
Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement.
Pigazzi M, Manara E, Buldini B, Beqiri V, Bisio V, Tregnago C, Rondelli R, Masetti R, Putti MC, Fagioli F, Rizzari C, Pession A, Locatelli F, Basso G. Pigazzi M, et al. Among authors: putti mc. Haematologica. 2015 Mar;100(3):e99-101. doi: 10.3324/haematol.2014.114579. Epub 2014 Dec 5. Haematologica. 2015. PMID: 25480496 Free PMC article. No abstract available.
Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.
Franca R, Rebora P, Bertorello N, Fagioli F, Conter V, Biondi A, Colombini A, Micalizzi C, Zecca M, Parasole R, Petruzziello F, Basso G, Putti MC, Locatelli F, d'Adamo P, Valsecchi MG, Decorti G, Rabusin M. Franca R, et al. Among authors: putti mc. Pharmacogenomics J. 2017 Jan;17(1):4-10. doi: 10.1038/tpj.2015.83. Epub 2015 Dec 8. Pharmacogenomics J. 2017. PMID: 26644204 Free article.
Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
Conter V, Valsecchi MG, Buldini B, Parasole R, Locatelli F, Colombini A, Rizzari C, Putti MC, Barisone E, Lo Nigro L, Santoro N, Ziino O, Pession A, Testi AM, Micalizzi C, Casale F, Pierani P, Cesaro S, Cellini M, Silvestri D, Cazzaniga G, Biondi A, Basso G. Conter V, et al. Among authors: putti mc. Lancet Haematol. 2016 Feb;3(2):e80-6. doi: 10.1016/S2352-3026(15)00254-9. Epub 2016 Jan 26. Lancet Haematol. 2016. PMID: 26853647
Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.
Buldini B, Rizzati F, Masetti R, Fagioli F, Menna G, Micalizzi C, Putti MC, Rizzari C, Santoro N, Zecca M, Disarò S, Rondelli R, Merli P, Pigazzi M, Pession A, Locatelli F, Basso G. Buldini B, et al. Among authors: putti mc. Br J Haematol. 2017 Apr;177(1):116-126. doi: 10.1111/bjh.14523. Epub 2017 Feb 27. Br J Haematol. 2017. PMID: 28240765 Free article.
Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL.
Locatelli F, Valsecchi MG, Möricke A, Zimmermann M, Gruhn B, Biondi A, Kulozik AE, Silvestri D, Bodmer N, Putti MC, Burdach S, Micalizzi C, Teigler-Schlegel A, Ritter J, Pession A, Cario G, Bielack S, Basso G, Klingebiel T, Vinti L, Rizzari C, Attarbaschi A, Santoro N, Parasole R, Mann G, Karawajew L, Haas OA, Conter V, Schrappe M. Locatelli F, et al. Among authors: putti mc. Blood. 2017 Nov 9;130(19):2146-2149. doi: 10.1182/blood-2017-05-782086. Epub 2017 Sep 22. Blood. 2017. PMID: 28939722 Free article. Clinical Trial. No abstract available.
A three-miRNA-based expression signature at diagnosis can predict occurrence of relapse in children with t(8;21) RUNX1-RUNX1T1 acute myeloid leukaemia.
Zampini M, Bisio V, Leszl A, Putti MC, Menna G, Rizzari C, Pession A, Locatelli F, Basso G, Tregnago C, Pigazzi M. Zampini M, et al. Among authors: putti mc. Br J Haematol. 2018 Oct;183(2):298-301. doi: 10.1111/bjh.14950. Epub 2017 Sep 29. Br J Haematol. 2018. PMID: 28961307 Free article. No abstract available.
137 results